Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.
In a real-world study, more than 54% of patients had at least 1 potentially actionable genomic alteration.
A subanalysis of the GOG 252 trial revealed factors associated with longer survival among patients with stage II-III epithelial ovarian cancer.
Niraparib reduced the risk of progression or death by 55%.
In one patient, progression would have been detected up to 143 days earlier with ctDNA than with conventional surveillance methods.
The response rate observed with mirvetuximab soravtansine was nearly triple the benchmark set in prior studies.
Open radical hysterectomy was associated with better outcomes at a median follow-up of 4.5 years.
The median overall survival was 147.8 months for patients with MAPK-mutated tumors and 89.5 months for patients without MAPK mutations.
In the first wave, 59% of respondents met criteria for low professional fulfillment, and 41% met criteria for burnout.
In a study of more than 5000 patients with advanced ovarian cancer, 56% received first-line maintenance therapy.
Intraperitoneal carboplatin can prolong progression-free survival, but not overall survival, in patients with ovarian cancer.
In a registry-based study, 5% of patients with gynecologic cancer died within 30 days of COVID-19 diagnosis.
Olaparib did improve the time to subsequent treatment and time to discontinuation or death.
Black and Hispanic patients are underrepresented in studies supporting NCCN guidelines for endometrial cancer.
The trend may be partially explained by increasing obesity rates, according to researchers.
The tool, called the “BLOODS score,” was developed to help identify patients who may benefit from preoperative planning and blood-saving techniques.
Data on overspending due to lenvatinib’s dose-specific packaging prompted the drug’s manufacturer to commit to changing its dose exchange program.
It may be time to revise US screening guidelines for cervical cancer in patients age 65 and older, according to researchers.
New data suggest that, contrary to popular belief, lesbian or bisexual women have a similar risk of HPV infection as heterosexual women.
The 4-year overall survival rate was similar with adjuvant chemotherapy and without it.
Including self-hypnosis as part of an enhanced recovery after surgery pathway proved feasible and produced high levels of patient satisfaction.